Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (all articles)

Meta-analysis of randomized trials: benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery.

10 Mar, 2022 | 10:48h | UTC

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials – The BMJ

 

Commentary on Twitter

https://twitter.com/KariTikkinen/status/1501532156786577415

 

Perspective: Once viewed as a promising COVID-19 treatment, convalescent plasma falls out of favor.

10 Mar, 2022 | 10:47h | UTC

Once Viewed as a Promising COVID-19 Treatment, Convalescent Plasma Falls Out of Favor – JAMA

 

Guideline: Implementing advance care plans in the peri-operative period, including plans for cardiopulmonary resuscitation.

10 Mar, 2022 | 10:40h | UTC

Implementing advance care plans in the peri-operative period, including plans for cardiopulmonary resuscitation: Association of Anaesthetists clinical practice guideline – Anaesthesia

 

RCT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure.

9 Mar, 2022 | 10:04h | UTC

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine

 

ACS Best Practice Guidelines: Spine injury.

9 Mar, 2022 | 10:00h | UTC

Spine Injury – American College of Surgeons

News Release: New guidelines will help trauma centers treat spinal injury patients

 

RCT: In patients with trauma-related hemorrhagic shock receiving prehospital care, there was no benefit from resuscitation with blood products compared to 0.9% sodium chloride.

9 Mar, 2022 | 09:55h | UTC

Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Haematology

Invited commentary: Prehospital blood transfusion: who benefits? – The Lancet Haematology

 

Commentary on Twitter

 

IDSA Guidance on the treatment of antimicrobial-resistant Gram-Negative infections – A focus on extended-spectrum β-lactamase producing Enterobacterales, Carbapenem-resistant Enterobacterales, and Pseudomonas aeruginosa with difficult-to-treat resistance.

9 Mar, 2022 | 08:51h | UTC

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0 – Infectious Diseases Society of America

Related:

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa – Infectious Diseases and Therapy

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

 

Doing more can be worse: ten common errors in the ICU.

8 Mar, 2022 | 08:51h | UTC

Doing More Can Be Worse: Ten Common Errors in the ICU – ICU Management & Practice

 

Study shows the number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance”.

8 Mar, 2022 | 08:57h | UTC

News Release: Number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance,” warn experts – BMJ

Original Study: SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis – The BMJ

Commentaries:

Lateral flow tests may be missing ‘substantial’ number of COVID-19 infections – Imperial College London

Self-testing for asymptomatic non-contacts using rapid antigen tests—is this leading to a cost effective reduction in infection transmission? – The BMJ

 

Fighting against sudden cardiac death: need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term prevention.

8 Mar, 2022 | 08:39h | UTC

Fighting against sudden cardiac death: need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term prevention – European Heart Journal

 

Commentary on Twitter

 

Case report: Nonthrombotic pulmonary embolism secondary to cyanoacrylate embolization of gastric varices.

8 Mar, 2022 | 08:35h | UTC

Nonthrombotic pulmonary embolism secondary to cyanoacrylate embolization of gastric varices – Canadian Medical Association Journal

 

RCT: In patients with stable chest pain with intermediate pretest probability of obstructive coronary artery disease, an initial diagnostic imaging strategy based on CT angiography resulted in similar risks of major adverse cardiovascular events compared to invasive coronary angiography.

7 Mar, 2022 | 00:55h | UTC

CT or Invasive Coronary Angiography in Stable Chest Pain – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: DISCHARGE Hailed as a Big Step Forward for CTA in Stable Chest Pain – TCTMD

 

Commentary on Twitter

 

RCT: Anterior–lateral electrode position is more effective compared to anterior–posterior electrode position for cardioverting atrial fibrillation.

7 Mar, 2022 | 00:45h | UTC

Anterior–Lateral Versus Anterior–Posterior Electrode Position for Cardioverting Atrial Fibrillation – Circulation

Commentary: Anterior-Lateral or Anterior-Posterior Pads for A-fib Cardioversion? – JournalFeed

 

Commentary on Twitter

 

Systematic Review: Anticoagulants for people hospitalized with COVID‐19.

7 Mar, 2022 | 00:48h | UTC

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Summary: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

Related: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

 

Systematic Review: Prediction of good neurological outcome in comatose survivors of cardiac arrest.

7 Mar, 2022 | 00:40h | UTC

Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review – Intensive Care Medicine

 

Commentary on Twitter

 

Ten myths about albumin.

7 Mar, 2022 | 00:44h | UTC

Ten myths about albumin – Intensive Care Medicine (free for a limited period)

 

Commentary on Twitter

 

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections.

7 Mar, 2022 | 00:09h | UTC

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

 

WSES guidelines on blunt and penetrating bowel injury: diagnosis, investigations, and treatment.

7 Mar, 2022 | 00:11h | UTC

WSES guidelines on blunt and penetrating bowel injury: diagnosis, investigations, and treatment – World Journal of Emergency Surgery

 

Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study.

7 Mar, 2022 | 00:00h | UTC

Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study – ERJ Open

 

Hepatorenal Syndrome Type 1: From diagnosis ascertainment to goal-oriented pharmacologic therapy.

6 Mar, 2022 | 23:47h | UTC

Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy – Kidney360

 

Distribution of delirium motor subtypes in the intensive care unit: a systematic scoping review.

6 Mar, 2022 | 23:38h | UTC

Distribution of delirium motor subtypes in the intensive care unit: a systematic scoping review – Critical Care

 

RCT: Preliminary trial suggests neostigmine may improve intra-abdominal hypertension and increase defecation in patients with acute pancreatitis.

6 Mar, 2022 | 23:39h | UTC

Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis – Critical Care

 

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

4 Mar, 2022 | 10:09h | UTC

News Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Original study: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Commentaries:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Related:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Commentary from the author on Twitter (thread – click for more)

 

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Related:

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Pre-post study: The introduction of a text-message alert system to alert volunteers close to a cardiac arrest patient at home was associated with increased survival to hospital discharge.

4 Mar, 2022 | 09:44h | UTC

Alert system-supported lay defibrillation and basic life-support for cardiac arrest at home – European Heart Journal

Editorial: Volunteer first responders for out-of-hospital cardiac arrest at home: the missing link for improved survival? – European Heart Journal

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.